In the clinic, the natural recovery rate of homonymous hemianopsia caused by occipital lobe infamtion is low. At present, ideal therapeutic effects of piracetam for improving visual field defects following homonymous ...In the clinic, the natural recovery rate of homonymous hemianopsia caused by occipital lobe infamtion is low. At present, ideal therapeutic effects of piracetam for improving visual field defects following homonymous hemianopsia do not exist. The present randomized, controlled study compared the effects of NeuroAid （MLC601） versus piracetam for improving visual field defects in post-infarct homonymous hemianopsia patients matched for age and sex. After 3 months of treatment with NeuroAid （MLC601） or piracetam, visual field defects were significantly improved, compared with prior to treatment （P 〈 0.001）. After treatment with MLC601, relative reduction of right and left visual field defects was 45% and 45.7%, respectively, while relative reduction after treatment with piracetam was 32.7% and 30.3%, respectively. These findings suggested that MLC601 was superior to piracetam for reducing visual field defects in homonymous hemianopsia patients.展开更多
目的:分析盐酸川芎嗪注射液联合吡拉西坦对急性脑梗死(Acute cerebral infarction,ACI)患者血液流变学及血清相关细胞因子水平的影响。方法:回顾性选取2021年5月至2024年4月我院收治的94例ACI患者为研究对象,依据不同治疗方案分为参照...目的:分析盐酸川芎嗪注射液联合吡拉西坦对急性脑梗死(Acute cerebral infarction,ACI)患者血液流变学及血清相关细胞因子水平的影响。方法:回顾性选取2021年5月至2024年4月我院收治的94例ACI患者为研究对象,依据不同治疗方案分为参照组和联合组(n=47),分别采用吡拉西坦以及吡拉西坦联合盐酸川芎嗪注射液治疗14 d。评估治疗14 d后临床疗效,并于治疗前、后采用美国国立卫生研究院卒中量表(National institute of health stroke scale,NIHSS)、脑卒中专门化生活质量表(Stroke-specific quality of life scale,SS-QOL)评估神经功能及生活质量,采用全自动血液流变仪、魏氏法检测血浆黏度、红细胞沉降率(Erythrocyte sedimentation rate,ESR)、全血黏度高切、全血黏度低切水平,采用酶联免疫吸附试验、比色法测定单核细胞趋化蛋白-1(Monocyte chemoattractant protein-1,MCP-1)、白细胞介素-6(Interleukin-6,IL-6)、神经元特异性烯醇化酶(Neuron-specific enolase,NSE)、同型半胱氨酸(Homocysteine,Hcy)、缺氧诱导因子-1α(Hypoxia inducible factor-1α,HIF-1α)、丙二醛(Malondialdehyde,MDA)、超氧化物歧化酶(Superoxide dismutase,SOD)水平,同时记录治疗期间安全性。结果:观察组临床疗效93.62%高于参照组78.72%(P<0.05);与参照组相比,治疗后联合组NIHSS评分更低,SS-QOL评分更高(P<0.05);联合组治疗后全血黏度低切、ESR、全血黏度高切、血浆黏度水平均低于参照组(P<0.05);治疗后联合组IL-6、Hcy、HIF-1α、MDA、MCP-1水平较参照组更低,NSE、SOD水平较参照组更高(P<0.05);两组不良反应发生率相比差异无统计学意义(P>0.05)。结论:盐酸川芎嗪注射液联合吡拉西坦治疗ACI效果显著,能改善血液流变学,抑制炎症发展,缓解神经损伤,促进生活质量恢复,安全性良好。展开更多
目的以氨甲环酸注射液和吡拉西坦注射液为代表,考察这两种治疗脑出血的注射剂与复方电解质醋酸钠葡萄糖注射液超说明书配伍的稳定性,为临床安全使用提供科学指导。方法将氨甲环酸注射液或吡拉西坦注射液与复方电解质醋酸钠葡萄糖注射液...目的以氨甲环酸注射液和吡拉西坦注射液为代表,考察这两种治疗脑出血的注射剂与复方电解质醋酸钠葡萄糖注射液超说明书配伍的稳定性,为临床安全使用提供科学指导。方法将氨甲环酸注射液或吡拉西坦注射液与复方电解质醋酸钠葡萄糖注射液配伍后,于0、1、2、4 h检测配伍溶液的澄明度、pH值、电导率、不溶性微粒和使用高效液相色谱法测定各自主药成分含量的变化。结果氨甲环酸配伍结果和吡拉西坦配伍结果均表明两种配伍溶液在室温放置4 h内未出现变色、气泡、沉淀、浑浊等明显外观变化;氨甲环酸注射液在配伍后0~4 h pH值、电导率的相对标准偏差(RSD)分别为0.10%、0.49%,吡拉西坦注射液在配伍后0~4 h pH值、电导率RSD分别为0.10%、1.50%;两者不溶性微粒均在《中国药典》规定范围内;氨甲环酸含量0~4 h RSD为1.90%;吡拉西坦含量0~4 h RSD为3.27%。结论氨甲环酸注射液或吡拉西坦注射液与复方电解质醋酸钠葡萄糖注射液配伍4 h内稳定。展开更多
文摘In the clinic, the natural recovery rate of homonymous hemianopsia caused by occipital lobe infamtion is low. At present, ideal therapeutic effects of piracetam for improving visual field defects following homonymous hemianopsia do not exist. The present randomized, controlled study compared the effects of NeuroAid （MLC601） versus piracetam for improving visual field defects in post-infarct homonymous hemianopsia patients matched for age and sex. After 3 months of treatment with NeuroAid （MLC601） or piracetam, visual field defects were significantly improved, compared with prior to treatment （P 〈 0.001）. After treatment with MLC601, relative reduction of right and left visual field defects was 45% and 45.7%, respectively, while relative reduction after treatment with piracetam was 32.7% and 30.3%, respectively. These findings suggested that MLC601 was superior to piracetam for reducing visual field defects in homonymous hemianopsia patients.
文摘目的:分析盐酸川芎嗪注射液联合吡拉西坦对急性脑梗死(Acute cerebral infarction,ACI)患者血液流变学及血清相关细胞因子水平的影响。方法:回顾性选取2021年5月至2024年4月我院收治的94例ACI患者为研究对象,依据不同治疗方案分为参照组和联合组(n=47),分别采用吡拉西坦以及吡拉西坦联合盐酸川芎嗪注射液治疗14 d。评估治疗14 d后临床疗效,并于治疗前、后采用美国国立卫生研究院卒中量表(National institute of health stroke scale,NIHSS)、脑卒中专门化生活质量表(Stroke-specific quality of life scale,SS-QOL)评估神经功能及生活质量,采用全自动血液流变仪、魏氏法检测血浆黏度、红细胞沉降率(Erythrocyte sedimentation rate,ESR)、全血黏度高切、全血黏度低切水平,采用酶联免疫吸附试验、比色法测定单核细胞趋化蛋白-1(Monocyte chemoattractant protein-1,MCP-1)、白细胞介素-6(Interleukin-6,IL-6)、神经元特异性烯醇化酶(Neuron-specific enolase,NSE)、同型半胱氨酸(Homocysteine,Hcy)、缺氧诱导因子-1α(Hypoxia inducible factor-1α,HIF-1α)、丙二醛(Malondialdehyde,MDA)、超氧化物歧化酶(Superoxide dismutase,SOD)水平,同时记录治疗期间安全性。结果:观察组临床疗效93.62%高于参照组78.72%(P<0.05);与参照组相比,治疗后联合组NIHSS评分更低,SS-QOL评分更高(P<0.05);联合组治疗后全血黏度低切、ESR、全血黏度高切、血浆黏度水平均低于参照组(P<0.05);治疗后联合组IL-6、Hcy、HIF-1α、MDA、MCP-1水平较参照组更低,NSE、SOD水平较参照组更高(P<0.05);两组不良反应发生率相比差异无统计学意义(P>0.05)。结论:盐酸川芎嗪注射液联合吡拉西坦治疗ACI效果显著,能改善血液流变学,抑制炎症发展,缓解神经损伤,促进生活质量恢复,安全性良好。
文摘目的以氨甲环酸注射液和吡拉西坦注射液为代表,考察这两种治疗脑出血的注射剂与复方电解质醋酸钠葡萄糖注射液超说明书配伍的稳定性,为临床安全使用提供科学指导。方法将氨甲环酸注射液或吡拉西坦注射液与复方电解质醋酸钠葡萄糖注射液配伍后,于0、1、2、4 h检测配伍溶液的澄明度、pH值、电导率、不溶性微粒和使用高效液相色谱法测定各自主药成分含量的变化。结果氨甲环酸配伍结果和吡拉西坦配伍结果均表明两种配伍溶液在室温放置4 h内未出现变色、气泡、沉淀、浑浊等明显外观变化;氨甲环酸注射液在配伍后0~4 h pH值、电导率的相对标准偏差(RSD)分别为0.10%、0.49%,吡拉西坦注射液在配伍后0~4 h pH值、电导率RSD分别为0.10%、1.50%;两者不溶性微粒均在《中国药典》规定范围内;氨甲环酸含量0~4 h RSD为1.90%;吡拉西坦含量0~4 h RSD为3.27%。结论氨甲环酸注射液或吡拉西坦注射液与复方电解质醋酸钠葡萄糖注射液配伍4 h内稳定。
